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Introduction 
 
Proteins are the working horses of a living cell. Within and 
around cells they perform a magnificently diverse set of functions. 
Besides providing structure and stability, proteins are involved in cell 
signaling, catalyzing reactions, storage and transport, and are therefore 
extensively studied. Over the years, tools have become available for 
researchers to reveal structure and function relationships, as well as 
localization and their interactions with other proteins.  
A relatively new tool is based on novel and specific chemistry. By 
modifying existing amino acids or introducing unnatural amino acids, 
proteins can be manipulated at the single amino acid level. Several 
methods involving the site-specific modification of proteins have been 
reported in the last decade. This allows the spatial and temporal 
control of proteins in vivo, as well as single molecule tracking. 
Modifications are introduced during protein translation, as post 
translational modification or chemically, after protein isolation.  
Besides their usefulness for in vitro/vivo research, site-specific 
modifications are also interesting for therapeutic applications. 
Pharmaceutical companies have been refocusing their pipeline towards 
biological medicines (mainly monoclonal antibodies) because of the 
high specificity and safety. The ‘naked’ monoclonal antibodies have 
shown to be very effective in blocking receptors. A next generation of 
biological medicines are the antibody drug conjugates (ADCs), which 
efficiently deliver the payload to the target limiting the off target 
effects. Interestingly, site-specific modifications have also been applied 
to improve the properties of these therapeutic proteins. 
Here, we review the tools for site-specific modification of 
proteins, followed by their applications in the development of 
therapeutic antibodies. 
  
 
 
 
 
 
 
 
 
  
 
 
 
Chemical modifications of proteins 
 
The oldest and most straightforward method for labeling proteins 
is via the primary amino groups on lysine residues and at the N-
terminus. In general, multiple accessible lysines and thus reactive 
amines are present on the protein surface, resulting in efficient 
labeling but inevitably leading to heterogeneous mixtures. Whether 
this method is applicable depends on the properties of the protein and 
the application. In the case of monoclonal antibodies, random labeling 
with fluorescent molecules hardly affects the antigen binding since 
many primary amines are present and only a small fraction may be 
important for this interaction. Smaller proteins such as antibody 
fragments are more likely to suffer from random conjugation due to a 
reduced number of lysines and the lack of an Fc region. There have 
been attempts to make this modification more specific by using 
preferential N-terminal labeling [ ] or kinetically controlled lysine 
labeling [2]. Generally those methods suffer from low yields or 
require complex steps including the recycling of the original protein. 
Besides labeling the amino groups, similar obstacles exist for 
conjugation via carboxyl groups [3] and will therefore not be 
discussed in detail.  
More selective is the labeling of proteins via sulfhydryl groups 
(also known as thiols). In proteins, most of the thiols are present in 
covalently linked pairs as disulfide bonds. The introduction of a 
cysteine by site-directed mutagenesis can be used for selective 
conjugation. Coupling reactions of maleimide groups with thiols have 
a high specificity over amines due to the lower pKa of the SH group 
(> 000 fold selectivity at pH 7.0) [4]. Therefore, cysteines are most 
commonly used for the site-selective modifications of proteins, 
though in some situations it is not feasible. One major drawback of 
introducing an extra cysteine is protein misfolding due to non-native 
disulfide bridge formation. In addition, thiol maleimide adducts have 
been reported to have limited stability in vivo [5]. Reactive thiols in 
albumin, free cysteine or glutathione can exchange with the existing 
thiol maleimide complex. Interestingly, hydrolysis of the succinimide 
ring prevented this exchange reaction [5]. Whether other alkylation 
reactions (with iodo/bromoacetamide analogs) also suffer from 
limited stability in vivo needs to be determined. Alternatively, an 
elegant double alkylation method by reducing disulfide bridges on the 
protein surface and subsequent conjugation with a PEG monosulfone-
enone reagent was stable in human serum for over 30 hours and did 
not affect the protein stability (scheme ) [6].  
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Next to direct protein modification via alkylation, a reduced 
cysteine can be first converted to dehydroalanine. Subsequent 
nucleophilic addition by thiol modified biomolecules label the target 
protein via a thioether bond. This method is a straightforward route 
to natural occuring cysteine modifications including phosphor [7], 
farnesyl [8] and N-acetylhexosamine cysteine [9], and to structural 
mimics of post-translational modifications, but generates epimeric 
products due to loss of the stereocenter in the first step. Recently, 
several strategies for the conversion of cysteine to dehydroalanine have 
been evaluated [ 0]. 
Over the years, several site-specific chemical modifications 
methods have been reported for the N-terminal amino acids. N-
terminal serine and threonine residues can selectively be oxidized by 
sodium periodate to form an aldehyde [ ], followed by oxime 
ligation [ 2]. Besides oxime ligation, the oxidized serine was recently 
also used for the one step N-terminal dual protein functionalization 
using strain promoted alkyne–nitrone cycloaddition [ 3]. 
Proteins with N-terminal cysteines have been successfully used for 
reactions with thioesters [ 4] and applied for fusion proteins through 
native chemical ligation [ 5], which will be described in more detail 
later on. 
More elegant methods are independent of the N-terminal amino 
acid. These approaches exploit the unique chemical properties of the 
N-terminus including the low pKa of the α-amino group of the N-
terminus (8.9) compared to the pKa of the lysine ε-amino group 
( 0.5). Kinetically controlled lysine labeling is performed in small 
steps, using multiple additions of the label and allowing the most 
reactive amino group to be preferentially labeled [2].  
Other methods are based on the introduction of unique reactive 
groups. The diazotransfer reagent imidazole- -sulfonyl azide was 
shown to specifically convert the N-terminal amino group into an 
azide group [ 6]. The N-terminus can also be converted into a ketone 
or aldehyde group by a transamination reaction [ 7]. Peptide library 
screening identified residues with high yields (A, G, D, E, N,), other 
amino acids were either not/less reactive or were prone to side 
reactions [ 8]. In more recent work the transamination reaction was 
demonstrated for labeling of a monoclonal antibody [ 9]. 
Alternatively, N-terminal modification based on ketenes was applied 
to introduce an alkyne in peptides and proteins [20]. This reaction is 
highly specific for most N-terminal amino acids but yields range from 
9 to 94%.  
Although these methods are generally straightforward for 
peptides, applications for proteins predominantly depend on the 
solvent accessibility of the N-terminus. Moreover, small modifications 
limit the usefulness of reactions with low yields due to difficulties in 
separating the modified from the unmodified proteins. 
 
Metabolic modifications 
 
Metabolic labeling of proteins involves the replacement of one or 
more canonical amino acids by non-canonical analogs. The first 
observations by Munier and Cohem showed the incorporation of 
phenylalanine and methionine analogs in bacterial proteins (red 
scheme in figure ) [2 ]. Since then, many analogs have been 
synthesized and tested in auxotrophic bacterial hosts for 
incorporation at the expense of canonical amino acids [22]. The strict 
biological machinery accepts only minor modifications such as alkenes 
[23], alkynes [24] and azides [24] as amino acid side chains. The 
latter being of particular interest due to their compatibility with the 
Staudinger ligation and (copper-free) click chemistry [25]. 
The occurrence of multiple phenylalanine or methionine residues 
in proteins results in protein mixtures upon conjugation. Recently 
though, only one out of five azidohomoalanines of native CalB was 
shown to be surface accessible and reactive for functionalization [26]. 
Instead of designing amino acid analogs to be accepted by the 
biological machinery, advances have been made to manipulate the 
biosynthetic apparatus itself. Mutations in phenylalanyl-tRNA 
synthetase (PheRS) caused either an increase or decrease of the 
binding pocket size, and thus a change in the specificity towards 
phenylalanine analogs (blue scheme in figure ) [27]. The unnatural 
amino acid  p-chlorophenylalanine could be incorporated 
into Photinus pyralis luciferase by expression of the mutant PheRS 
(A294G) in E. coli, replacing all phenylalanines [28]. More recently, 
the same has been demonstrated for non-canonical analogs using 
mutations in LeuRS [29], PheRS [30] and ValRS [3 ]. 
Scheme 1. Double alkylation of proteins by PEG monosulfone-enone. 
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Both previous methods relied on the global replacement of 
canonical amino acid in proteins. The first site-specific modification 
of a single amino acid (based on editing the biological machinery) has 
been reported by Schultz [32] and Chamberlin [33] (yellow scheme 
in figure ). Non-canonical amino acids were incorporated upon 
suppression of the amber nonsense codon (TAG) by chemically 
acylated suppressor transfer RNA. In theory, also the two other stop 
codons could be targeted. However, the least used codon 
(TAG/amber codon) was selected to minimize the effect of 
translation read through on other proteins by suppression of the stop 
codon. This approach was first limited to in vitro production of 
proteins, or in vivo by microinjection into oocytes [34]. Later on, next 
to the gene of interest also the synthetase/tRNA pair was expressed 
in vivo. Efforts by Schultz and coworkers have improved this 
approach by applying selection schemes to reduce the interaction with 
the biological machinery [35,36]. These include the selection with 
toxic genes bearing several amber codons to reduce the incorporation 
of canonical amino acids, as well as GFP expression in the presence of 
the unnatural amino acid to screen for the highest incorporation. In 
another example the whole biological machinery for the synthesis and 
incorporation of the 2 st amino acid was introduced in E. coli [37]. 
Moreover, the methodology has also been transferred to yeast and to 
mammalian cell lines by stable transfection. 
Next to the suppression of non-sense codons, frame shift 
suppression has been used for the site-specific introduction of non-
canonical amino acids [38]. This allows for not the triplet-base codon 
but codons containing 4 or 5 bases to be recognized. The usage of 
frameshift codons is complicated by competition by the endogenous 
triplet recognizing tRNA, resulting in a -  frameshift and a premature 
termination. Alternatively, the frameshift suppressor tRNA could also 
recognize endogenous codons (3+ ), causing a +  frameshift and a 
premature termination as well. The selection of four-base codons 
based on genetic occurrence frequency allowed the incorporation of 
multiple unnatural amino acids in vivo [39]. 
Efforts over the years have allowed over 70 novel amino acids to 
be genetically incorporated via this approach, including 
photocrosslinkers, photocaged groups and fluorescent labels [37].  
 
Post translational modifications 
 
After translation, almost all proteins require post-translational 
modifications (PTMs) before becoming mature. The oxidation of 
cysteines is a common PTM and is important for protein folding and 
stability. Other PTMs increase the functional diversity of proteins by 
the modification of amino acids including phosphorylation, 
glycosylation, ubiquitination, nitrosylation, methylation, acetylation 
and proline cis-trans isomerization [40]. Site-specific enzymatic 
PTMs are of particular interest since they can be used to manipulate 
and/or study proteins.  
 
Lipid modifications change the subcellular localization of proteins 
and can affect protein function [4 ]. Farnesyl- and N-
myristoyltransferases recognize a consensus motif (CAAX and 
GXXXS/T) on proteins and subsequently conjugate farnesyl and 
myristoyl groups, respectively [42,43]. Azide functionalized analogs 
of those groups have been used to label and study proteins [44,45]. 
Although these transferases are sequence specific, the subcellular 
localization limits the applications for other proteins. 
Another more random modification is introduced by 
transglutaminases (TGs), which cross-link proteins with isopeptide 
bonds between Lys and Gln residues [46]. TGs are involved in cell 
adhesion, stabilization of the extracellular matrix, apoptosis and 
wound healing. Importantly, multilayered epithelium, stabilized by 
these cross-links, protects the organism from the environment. The 
random crosslinking activity limits the possible applications of TGs. 
Cell surface proteins bearing a Q-tag (PNPQLPF, PKPQQFM, 
GQQQLG, and the recently identified RLQQP [47]) have been 
successfully labeled with biotin and fluorescein, though background 
labeling was observed [48]. 
 
In another approach the native formylglycine generating enzyme 
(FGE) is used to introduce formylglycine in both prokaryotes[49] 
and eukaryotes [50]. The aldehyde tagged protein can be readily 
functionalized with aminooxy- or hydrazide-functionalized 
biomolecules [50]. A drawback is the hydration of formyglycine in 
water to the diol-formylglycine, lowering the yield to around 85% 
[5 ].  
 
Besides the modification of other proteins, some enzymes can be 
used for self-modification such as human O6-alkylguanine-DNA 
alkyl transferase (hAGT) [52], cutinase [53] and halo alkane 
dehalogenase [54]. Structural analogs of the natural substrates temper 
the biological function of hAGT and cultinase. A single mutation in 
halo alkane dehalogenase (His272Phe) traps the protein at an 
intermediate state and allows covalent attachment of chemical 
probes[54]. Fusion proteins bearing these domains can be selectively 
modified in vitro or in vivo [55–57]. Compared to other approaches, 
the large size of these domains (2 -33 kDa) is considered as the 
major drawback. This can influence the function and/or localization 
of the protein of interest by the interaction with other biomolecules. 
Nevertheless, hAGT is commonly used for cell imaging studies 
because of the high labeling efficiency and of cell permeable probes 
[55,58]. 
 
A straightforward class of enzymes for modifying proteins after 
translation are the ligases (figure 2). Ting and coworkers have been 
involved in exploiting several enzymes for site-specific modifications. 
First, biotin ligase (BirA) was shown to accept also a ketone isostere 
of biotin as a cofactor [59]. Ligation of this biotin analog to proteins 
Figure 1. Metabolic labeling of proteins. The global replacement of natural 
amino acids by non-canonical analogs (red). Increased specificity for 
unnatural amino acids by manipulating the biosynthetic machinery (blue). 
Site-specific incorporation of unnatural amino acids by an orthogonal 
aminoacyl-tRNA synthetase/tRNA pair (yellow). 
Site-specific functionalization of proteins 
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bearing the 5-amino-acid acceptor peptide (AP) was demonstrated 
in vitro and in vivo, followed by subsequent ketone-hydrazine 
conjugation. Second, the microbial lipoic acid ligase (LplA) was used 
to specifically attach an alkyl azide onto proteins with an engineered 
LplA acceptor peptide (LAP) [60]. Although only 33% could be 
converted [6 ], cell surface labeling with cyclo-octyne probes was 
demonstrated [60]. Mutants of LplA were shown to be more 
efficient[6 ] (up to 89%) and also transfer fluorinated aryl azide [62] 
and 7-hydroxycoumarin [63] to LAP proteins for photocrosslinking 
and life cell imaging, respectively. More recently the portfolio of 
lipoic acid ligase was extended to ligate a trans-cyclooctene [64]. The 
Diels-Alder cycloaddition allows rapid labeling of inner and outer 
cellular proteins, though the yield is unknown. 
 
 
 
 
 
 
 
Another set of post-translational modifications is performed by 
phosphopantetheinyl transferases (PPTases) [65]. PPTases are 
categorized into Sfp-like (B. subtilis) [65], AcpS-like (E. coli) [66] 
and FAS2-like (S. cerevisiae) [67] subfamilies and transfer a 
phosphopantetheinyl (P-pant) group through a phosphodiester bond 
onto peptidyl/acyl carrier protein (PCP/ACP) domains. These 
typically 80– 20 residues long domains are present on nonribosomal 
peptide synthetases (NRPSs), polyketide synthases (PKSs), and fatty 
acid synthases (FASs)[65].  
Broad substrate specificity [68] and rapid conversion (>80% after 
30 min) [69] was reported for Sfp-based labeling of proteins with 
phosphopantetheinylated analogs. In order to overcome possible size 
limitations, phage display screening identified several / 2-residue 
peptide tags as replacement for the carrier domain, each allowing the 
labeling of N- or C-termini as well as flexible loops on target proteins 
[69,70]. Interestingly, orthogonal fluorescent labeling of cell surface 
receptors was demonstrated by using Sfp and AcpS selective peptide 
tags [70]. 
 
Instead of exploring the chemical space in which biomolecules can 
be modified by functional groups and subsequently incorporated in 
proteins of interest, some general applicable enzymatic modifications 
preexist in nature. Sortases function as transpeptidase anchoring 
proteins to the bacterial cell wall [7 ]. Upon recognition of the 
sorting motif LPXTG (or LPXTA) a catalytic cysteine cleaves the 
peptide bond between residue T and G, yielding a thioacyl 
intermediate [72]. Instead of hydrolysing a peptide bond (as in the 
case of cysteine proteases), sortases accept a N-terminal (oligo)glycine 
as a nucleophile, creating a new peptide bond between the two 
molecules (figure 3). 
 
 
 
 
 
 
 
 
Sortases function at physiological conditions and have been used 
for protein labeling with various functionalities such as biotin, 
fluorophores, cross-linkers and multifunctional probes [73]. Target 
proteins are commonly labeled C-terminally with the LPXTG sorting 
motif, followed by a purification tag. Subsequent transpeptidation 
removes the purification tag and generates the labeled proteins in high 
yields. Interestingly, this approach has also been used to study the 
structure and function of a solvent-exposed loop within the ubiquitin 
C-terminal hydrolase 3 protein [74]. 
Besides introducing the sorting motif, proteins can also be 
equipped with a N-terminal (oligo)glycine for N-terminal 
conjugation. In this case, the sortase recognition element should be 
introduced onto the biomolecule. This approach has mostly been used 
for bacterial cell wall labeling with biotin, azide and fluorescent 
groups [73]. 
Alternatively, also both N- and C-terminal ligation has been 
demonstrated [75]. Selective labeling is achieved by using two sortases 
with different specificity (LPXTG & LPXTA), preventing the 
oligomerisation of proteins. Protein cyclisation occurs in cases where 
the N- and C-termini are in close proximity [76,77]. This is of 
particular interest in therapeutic drug design due to the enhanced 
conformational stability and increased resistance to proteolytic 
cleavage [78]. 
The fusion of two proteins can be achieved in a similar fashion, 
with each protein bearing one of the tags. Although genetic fusion of 
proteins is much more straightforward, in some cases this is not 
feasible. For instance when protein folding is affected, protein yields 
drop or proteins come from different hosts. In a recent study, 0 
pairs of protein domains were generated with yields between 40-85% 
[79]. 
The labeling of proteins by sortases has been optimized and well 
described. One of the major drawbacks is the high concentration of 
sortase required. The poor reaction kinetics have been improved 40-
fold using directed evolution by increasing the affinities for the 
sorting motif LPXTG as well as the (oligo)glycine peptide [80]. 
Figure 2. Protein modification by ligases at the N/C-terminus and in 
flexible loops. 
Figure 3. N- and C-terminal protein modification by sortases. Although 
sortase recognition sites have been engineered in flexible loops of 
proteins, the subsequent cleavage of the peptide backbone limits its 
therapeutic applications. 
Site-specific functionalization of proteins 
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Inteins, also known as protein introns, are protein domains 
expressed in frame of another protein [8 ]. Removal of the intein 
domain by self-excising, rejoins the two external host protein 
segments by formation of a native peptide bond, and restores the 
function of the host protein.  
This process can be exploited for the N/C-terminal ligation of 
biomolecules (figure 4) [82]. The C-terminal labeling requires the 
formation of a thioester by nucleophilic attack of the intein N-
terminal cysteine. The thiol can be exchanged in the presence of thiol 
reagents, resulting in cleavage of the intein. In a subsequent native 
chemical ligation reaction with a cysteine functionalized molecule, the 
thiol exchanges again followed by the generation of a peptide both by 
the S-N shift. The C-terminal intein mediated conjugation has been 
demonstrated for labeling with biotin [83], fluorophores [84] and 
lipids [85,86]. Moreover, semi synthetic proteins were produced by 
the ligation of cysteine bearing peptides, known as expressed protein 
ligation [87]. 
The N-terminal labeling also requires the exchange of thiols for 
cleaving off the intein. Now the intein C-terminal asparagine breaks 
the peptide bond, freeing an N-terminal cysteine on the protein of 
interest. Labeling of N-terminal cysteine is performed in the same 
NCL reaction with a thioester modified biomolecule and has been 
used to immobilize proteins on microarrays [88] as well as for in vivo 
labeling [89].  
Inteins can, similarly to sortases, also facilitate the cyclisation of 
proteins[82]. The commercialized IMPACT kit allows 
straightforward production and purification of proteins with an N- 
and/or C-terminal modification for site-specific functionalization 
[ 5,90]. As the intein domain is coexpressed, no other proteins are 
required. However, reactions in complex mixtures are challenging 
since thioesters can be inactivated by reactions with amines and by 
hydrolysis [9 ]. 
 
 
 
 
 
 
The covalent attachment of carbohydrate chains (glycans) to 
proteins is the most prevalent and complex PTM, also known as 
glycosylation [92]. Glycans can be N-linked to proteins via the 
asparagine or arginine side-chain, or O-linked via the hydroxyl group 
mostly on serine, threonine and tyrosine, and also hydroxylysine, or 
hydroxyproline side-chains [93]. Although the majority of the 
glycoproteins are present on the exterior surface of cells, the O-
GlcNAc modification has also been reported for proteins in the 
cytosol and nucleus [94]. 
Glycosylation is important for protein folding and stability, 
thereby affecting the circulation lifetime in blood (discussed later on) 
[95]. Interestingly, the PTM itself can be used for subsequent 
modification of glycoproteins via bioorthogonal chemistry. For 
instance, the metabolic labeling of glycans is achieved by feeding cells 
or organisms with modified glycan precursors [96]. Several azido 
sugars including N-azidoacetylmannosamine (ManNAz), N-
azidoacetylgalactosamine (GalNAz), N-azidoacetylglucosamine 
(GlcNAz) and 6-azidofucose (6AzFuc) have been incorporated into 
glycoproteins by the glycan biosynthetic machinery in both in vitro 
and in vivo [97]. In addition, attempts have been made to 
enzymatically label glycoproteins. For example the permissive mutant 
β- ,4-galactosyltransferase (Gal-T  (Y289L)) introduces azido 
galactosamine (GalNAz) onto O-GlcNAc–modified glycoproteins 
[98,99]. The introduced azido group allows subsequent glycan-
profiling and visualization of proteins of interest [98]. 
Although the glycan modification of glycoproteins expands the 
researcher’s toolbox, the great structural complexity limits its 
applications today. Especially the glycan recognition by the immune 
system affects the usefulness for therapeutic proteins [ 00]. Attempts 
to overcome these problems involve exploring the production of 
therapeutic glycoproteins in different hosts and addressing (chemo) 
enzymatic methods to derive homogeneous glycosylation patterns. 
 
Applications for therapeutic antibodies 
 
Traditionally, drugs have been small chemical entities based on 
natural and (semi)synthetic products [ 0 ]. Analogs of natural active 
compounds have been optimized for physicochemical and 
pharmacological properties allowing oral administration while 
maintaining therapeutic efficacy. The lack of specificity and/or the 
inability to block protein-protein interactions by these small chemical 
entities stimulated the development of protein based drugs [ 02]. 
Certain type of proteins such as hormones and antibodies naturally 
bear very high specificity for their target. Moreover, their natural 
appearance in the human body makes them reasonably safe as 
therapeutic compounds. Protein drugs, however, often suffer from 
other issues such as low stability, poor pharmacokinetics, limited 
efficacy and require a complex route of administration [ 03, 04]. 
Over the years, research groups and pharmaceutical companies have 
made various attempts to improve these parameters by modifying 
therapeutic proteins using some of the above mentioned methods 
[ 05]. The second part will review these modifications. 
 
In vivo responses of (protein) therapeutics are influenced by drug 
absorption, distribution, metabolism and excretion (ADME). Small 
sized proteins are predominantly cleared via glomerular filtration by 
the kidneys [ 06]. This results in a half-life of 2 hours for single-
domain antibodies ( 5 kDa) [ 07] and 2-20 hours for Fab 
fragments (50 kDa) [ 08]. Proteins above the glomerular filtration 
cutoff (molecular weight >50 kDa and hydrodynamic radius >60 Å) 
are cleared by other pathways including proteolytic degradation, 
hepatic uptake and immune clearance[ 09]. Monoclonal antibodies, 
for instance, are 50 kDa and have long half-lives (7-23 days) by 
default [ 0]. 
The elimination of small proteins by the kidneys can thus be 
influenced by modifications affecting the size. The covalent 
attachment of water soluble polymers to proteins (such as 
polyethylene glycol; PEG) increases the hydrodynamic size and 
interestingly also reduces the immunogenicity by masking the protein 
from the immune system [ ]. Several branched and non-branched 
PEG structures have been evaluated for the effect on renal clearance. 
Enhanced PK profiles for branched PEG conjugates have consistently 
Figure 4. Intein-mediated conjugation of biomolecules. 
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been described for therapeutic proteins in the literature [ 2– 4]. 
Recently for instance, single domain antibodies labeled with 2x20 
kDa PEG were shown to be superior over x40 kDa and 4x 0 kDa 
labeling without affecting the biological activity [ 4]. 
Biodistribution studies showed higher serum exposure of the 
antibody, though this was not the case for some tissues.  
Although PEG is considered as the golden standard in drug 
delivery, antibody formation against PEG conjugates was reported in 
983 already [ 5]. Interestingly, preexisting antibodies against PEG 
were found in healthy donors of the PEG-asparaginase clinical trial 
[ 6]. And even, a more rapid blood clearance of PEG conjugates was 
observed in patients with existing anti-PEG antibodies [ 6, 7]. 
This may seriously affect the applications of PEG for drug delivery 
due to an expected reduced therapeutic efficacy in patients with 
antibodies against PEG. 
These issues stimulated researchers to find alternative polymers 
including non-biodegradable poly(glycerol)s, poly(vinylpyrrolidone), 
poly(2-oxazoline)s, poly(N-(2-hydroxypropyl)methacrylamide), and 
biodegradable poly(amino acid)s. Promising results were reported for 
some alternatives, however the current understanding is very limited 
and requires additional (clinical) studies. A recent review by Knop et 
al. discusses PEG and potential alternatives in more detail [ 8].  
Monoclonal antibodies on the other hand have already a long 
half-life. For therapeutic purposes, the IgG class has predominantly 
been used. Within the IgG class, the IgG subclasses -4 differ in the 
Fc region which affects effector functions such as phagocytic cell 
recruitment and complement activation through cellular IgG-Fc 
receptors, and in half-life by recycling via neonatal Fc receptor (FcRn) 
[ 9]. The strong effector effects and long half-life of subclass IgG  
are ideal for antibody based therapy in oncology [ 20]. Other 
treatments such as in Crohn’s disease mainly depend on antigen 
neutralization. Here, the effector functions by the Fc region can give 
rise to side effects. This led to the development of a pegylated IgG -
Fab (Certolizumab pegol) next to the existing IgG ’s infliximab and 
adalimumab, which misses the Fc region [ 2 ]. An additional benefit 
is the lack of active transport by FcRn across the human placenta and 
thus the antibody should be safe in pregnancy. Alternatively strategies 
to reduce/remove effector functions are IgG isotype switching to 
IgG2/4 and removal of glycosylation sites [ 22]. The latter can be 
achieved either by mutation of asparagine 297 in the CH2 domain 
(and additional glycosylation sites) or by expression of antibody 
(fragments) in prokaryotic hosts.  
 
Biodistribution is another factor determining the efficacy of 
antibody therapy, and varies per Ig class due to differences in the Fc 
region. The distribution of IgG class monoclonal antibodies is mainly 
confined to blood and extracellular fluid. Pegylation of antibody 
fragments was reported to influence the biodistribution [ 23]. Since 
the therapeutic response of antibody therapy depends on the drug 
concentration at the target site, many studies have analyzed impaired 
distribution in tumors [ 24– 26]. Compared to normal tissue, the 
interstitial hydrostatic pressure and missing lymphatic draining 
restricts movement of antibodies [ 26]. Consequently, invasion of 
monoclonal antibodies occurs predominantly via diffusion across 
pores in the capillary and is limited by the molecular size. In addition, 
the ‘binding site barrier’ limits deep penetration of antibodies into 
tumors[ 27, 28]. Diffusion and convection are restricted to the outer 
layer of cancer cells due to high affinity, rapid internalization and 
subsequent metabolism of antibodies [ 29].  
Taken together, tumor penetration can be improved by targeting 
smaller sized antibodies including single-domain antibodies and Fab 
fragments. These antibody fragments lack an Fc region and therefore 
have a reduced half-live. Whether the improved tumor penetration is 
sufficient to compensate for the shorter circulation time needs to be 
evaluated. 
 
The molecular weight of monoclonal antibodies is beyond the 
filtration cutoff of the kidneys. Still, the half-life between IgG 
subclasses ranges from 7 to 23 days [ 0]. The interaction between 
the Fc region and the FcRn receptor, has been suggested as one of the 
determining factors. Where normally the uptake of proteins by 
vascular endothelial cells would result in degradation in lysosomes, 
antibodies are recycled back into the circulation as a consequence of 
their interaction with the FcRn receptor [ 30]. Validation in FcRn 
knockout mice showed a 0- 5x higher IgG elimination while other 
classes were not affected [ 3 – 33]. In addition, engineered tighter 
binding to the FcRn resulted in a 2-fold increase in the half-life in 
monkeys [ 34]. Other factors determining the clearance rate of 
antibodies are immunogenicity, proteolysis and glycosylation [ 35]. 
Interestingly, the production of hyperglycosylated antibodies 
fragments in engineered cell lines demonstrated longer half-lives as 
well as reduced proteolysis [ 09]. Alternatively, Fab fragments 
conjugated to PEG benefits, beside from the increased size, also from 
the reduced intracellular uptake and proteolytic degradation by 
masking sensitive sites [ 4]. 
 
The next generation of biological medicines are the antibody drug 
conjugates (ADCs) [ 36]. Where ‘naked’ monoclonal antibodies rely 
on the recruitment of immune cells by the Fc region for its toxicity, 
ADCs bear a stable (or selective cleavable) linkage with a cytotoxic 
payload [ 37]. The release of the payload after 
absorption/internalization by the target cell minimizes exposure of 
healthy tissues [ 37]. More importantly, because of the cytotoxic 
payload, ADCs are more effective in the killing of cancer cells [ 38]. 
An interesting example is the monoclonal antibody trastuzumab 
(Herceptin), which targets Her2 over-expression on certain types of 
breast cancer [ 39]. Trastuzumab has been marketed since 998 and 
predominantly inhibits tumor proliferation. Recently, ADC 
trastuzumab emtansine (Kadcyla) was approved by the FDA. The 
delivery of cytotoxic emtansine induces microtubule disruption, 
thereby making this construct more effective (54% longer median 
progression-free survival compared to trastuzumab plus docetaxel) 
[ 40, 4 ]. Between 0 and 8 emtansine molecules are randomly 
conjugated via the SMCC crosslinker onto lysine residues on 
trastuzumab (3.5 on average)[ 40]. Because of the on average 00 
lysines per antibody, this results in a heterogeneous mixture. A 2/3-
fold faster clearance of trastuzumab emtansine compared to the naked 
antibody has been attributed to deconjugation and proteolytic 
degradation of the ADC [ 42].  
Better defined is the monoclonal antibody brentuximab vedotin 
(Adctris) for treating Hodgkin's lymphoma. Mild reduction by 
dithiothreitol (DTT) generates 8 thiol groups from four interchain 
disulfide bridges [ 43]. Monomethyl auristatin E (MMAE) is 
conjugated to 3-5 thiol groups (4 on average). Although labeling of 
brentuximab with 8 MMAE molecules has also been reported, the 
higher degree of labeling generally results in faster clearance/shorter 
half-life. Interestingly, the in vivo antitumor activity was comparable 
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for ADCs bearing 4 or 8 MMAE molecules (at equal mg/kg/dose) 
[ 44].  
Off target/side effects by ADCs can generally be explained by 3 
situations: ) The antibody is not specific enough causing 
accumulation in healthy tissue; 2) The cytotoxic agent is lost before it 
reaches the target cell; or 3) The heterogeneous population has altered 
speciﬁcities or pharmacokinetics. The drawbacks of producing 
monoclonal antibodies as heterogeneous product led to the site-
specific incorporation of unnatural amino acids in monoclonal 
antibodies and antibody fragments [ 45– 47]. A defined 
stoichiometry and stable linkage is expected to reduce the side effects 
of ADCs. In addition, optimal sites for conjugation can be selected to 
reduce the effect on the circulation time.   
In order to demonstrate this, a noncleavable auristatin analog was 
conjugated to trastuzumab bearing the unnatural amino acid p-
acetylphenylalanine (pAcF) [ 46]. The functionalized ADC was 
obtained in an overall yield of >95% and showed a similar clearance 
rate as the naked antibody. 
Currently, the companies Allozyne, Ambrx and Sutro explore the 
incorporation of unnatural amino acids for its therapeutic 
applications. An overview of FDA approved ADCs is given in table . 
 
Next to ADCs, also the recruitment of T-cells by bispecific 
antibodies is effective for the treatment of cancer. Bispecific 
antibodies recognize tumor specific antigens and T-cells at the same 
time [ 49]. In one strategy, random crosslinking has been applied to 
conjugate two antibodies together via hetero-bifunctional crosslinkers 
such as SPDP (succinimidyl-3(2-pyridylthiol)propionate) [ 50– 52] 
and SMCC (Succinimidyl-4-(N-maleimidomethyl)cyclohexane- -
carboxylate) [ 53]. Monoclonal antibodies however bear two 
fragment antigen-binding sites (Fab fragment) both recognizing the 
same antigen. Selective reduction of disulfide bonds and subsequent 
oxidation was used to acquire monovalent bispecific antibody 
fragments (one Fab for each antigen) [ 54]. 
More recently, uniform bispecific antibodies were generated by 
first expressing two sets of half-antibodies which were unable to 
dimerize [ 55]. The bispecific antibodies were spontaneously formed 
by mixing the reduced half-antibodies under oxidizing conditions. In 
contrast, the only FDA approved bispecific antibody therapy 
(Catumaxomab) is directly produced in hybrid mouse/rat quadroma 
cell lines [ 56]. Due to the homology in the hinge region between 
mouse and rat antibodies, the 30-49% yield almost reached the 
statistical limit of 50% (m/m, m/r, r/m and r/r) [ 57]. Besides 
binding tumor cells via the EpCAM antigen and T-cells via the CD3 
receptor, the intact Fc region of Catumaxomab recruits accessory cells 
to enhance the immune response against the tumor [ 58]. 
Next to the generation of full monoclonal antibodies, two Fab 
fragments bearing genetically encoded unnatural amino acids were 
conjugated to form an anti-HER2/anti-CD3 bispeciﬁc 
antibody[ 45]. The confined sites and defined chemistry allowed 
homogeneous products in a two-step process. Although effective 
tumor killing was observed in vitro, the efficacy in vivo still needs to 
be determined. 
 
Based on antibody complexes in nature, immune complexes have 
emerged for the neutralization of antigens. Binding to tumor specific 
antigens blocks signaling cascades as well as causes down-regulation of 
the receptor [ 59]. Diverse set of scaffolds including avidin [ 60], 
gold [ 6 ], liposomes [ 62] and polymersomes [ 63– 66] have been 
decorated with antibodies or antibody fragments. Recently, DNA 
scaffolds decorated with single-domain antibodies were demonstrated 
to allow various structures such as dimers and tetramers [ 47].  
Besides immune complexes binding to antigens, the subsequent 
internalization has drawn attention for the delivery of drugs. 
Compared to current ADCs, nanocapsules facilitate the delivery of 
high drug concentrations by active (antibody binding) and passive 
targeting (EPR effect; beyond the scope of this review, see ref [ 67]). 
In order to remain in the blood circulation, nanoparticles need to 
meet several criteria including confined size, shape and chemical 
properties [ 68]. Antibody fragments are often used for the targeting 
of nanocapsules because no Fc region and subsequent signaling 
cascade is required. Since none of these nanomedicines have been 
FDA approved, an overview of decorated nanoparticles in clinical 
trials is given in table 2. 
 
Summary and Outlook 
 
Site-specific modification of proteins has emerged as powerful 
tool to study proteins at the single amino acid level. Currently, the 
field is expanding towards applications for therapeutic proteins. 
Several studies have demonstrated the usefulness of unnatural amino 
acids in antibody drug conjugates. The time-consuming drug 
development and approval process has delayed the integration of these 
methods for therapeutic antibodies, but this can be expected in the 
near future. 
In contrast to therapy, the approval process for diagnostic 
antibodies is shorter. The functionalization methods described in this 
review would be ideal to label antibodies with diagnostic tracers 
(radioactive, fluorescent or contrast agents), but will be even more 
important for the successful development of theranostics, a one-
molecule combination of diagnosis and therapy. 
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Table 2. Antibody decorated nanoparticles in clinical trials.
it i
II [169J
Name Particle Drug
Erbitux EDVsPAC Bacterially-derived minicell Paclitaxel
SGT-53 Liposome p53 gene
MM-302 Liposome Doxorubicin
Lipovaxin-MM Liposome Melanomaantigens and IFNy
SGT-94 Liposome RB94gene
C225-ILS-DOX Liposome Doxorubicin
MCC-465 Liposome Doxorubicin
* Clinical trial is performedin 2004, current status is not available.
Chemistry
NA
NA
NA
Cysteine
Lysine
Target Antibody
EGFR mAb
Transferrin scFv
HER2 Fab
DC-SIGN sdAb
Transferrin scFc
EGFR Fab (cetuximab)
Unknown Fabl
Phase
IbIII
1*
Ref
[170J
[171J
NA
NA
[172J
[173J
-
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